152 related articles for article (PubMed ID: 27293986)
1. Prolactin-induced protein as a potential therapy response marker of adjuvant chemotherapy in breast cancer patients.
Jablonska K; Grzegrzolka J; Podhorska-Okolow M; Stasiolek M; Pula B; Olbromski M; Gomulkiewicz A; Piotrowska A; Rys J; Ambicka A; Ong SH; Zabel M; Dziegiel P
Am J Cancer Res; 2016; 6(5):878-93. PubMed ID: 27293986
[TBL] [Abstract][Full Text] [Related]
2. Prolactin-induced protein (PIP) increases the sensitivity of breast cancer cells to drug-induced apoptosis.
Urbaniak A; Jablonska K; Suchanski J; Partynska A; Szymczak-Kulus K; Matkowski R; Maciejczyk A; Ugorski M; Dziegiel P
Sci Rep; 2023 Apr; 13(1):6574. PubMed ID: 37085653
[TBL] [Abstract][Full Text] [Related]
3. Prolactin Induced Protein (PIP) is a potential biomarker for early stage and malignant breast cancer.
Gangadharan A; Nyirenda T; Patel K; Jaimes-Delgadillo N; Coletta D; Tanaka T; Walland AC; Jameel Z; Vedantam S; Tang S; Mannion C; Lee GY; Goy A; Pecora A; Suh KS
Breast; 2018 Jun; 39():101-109. PubMed ID: 29656222
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.
Maeda T; Nakanishi Y; Hirotani Y; Fuchinoue F; Enomoto K; Sakurai K; Amano S; Nemoto N
Med Mol Morphol; 2016 Mar; 49(1):11-21. PubMed ID: 26009308
[TBL] [Abstract][Full Text] [Related]
5. [Analysis of prolactin receptor expression in breast cancer subtypes].
Kalinina TS; Kononchuk VV; Sidorov SV; Gulyaeva LF
Biomed Khim; 2020 Jan; 66(1):89-94. PubMed ID: 32116231
[TBL] [Abstract][Full Text] [Related]
6. Expression of matrix metalloproteinases (MMPs) in primary human breast cancer: MMP-9 as a potential biomarker for cancer invasion and metastasis.
Merdad A; Karim S; Schulten HJ; Dallol A; Buhmeida A; Al-Thubaity F; Gari MA; Chaudhary AG; Abuzenadah AM; Al-Qahtani MH
Anticancer Res; 2014 Mar; 34(3):1355-66. PubMed ID: 24596383
[TBL] [Abstract][Full Text] [Related]
7. The influence of breast cancer subtypes on the response to anthracycline neoadjuvant chemotherapy in locally advanced breast cancer patients.
Stamatovic L; Susnjar S; Gavrilovic D; Minic I; Ursulovic T; Dzodic R
J BUON; 2018; 23(5):1273-1280. PubMed ID: 30570847
[TBL] [Abstract][Full Text] [Related]
8. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
Karatas F; Erdem GU; Sahin S; Aytekin A; Yuce D; Sever AR; Babacan T; Ates O; Ozisik Y; Altundag K
Breast; 2017 Apr; 32():237-244. PubMed ID: 27318645
[TBL] [Abstract][Full Text] [Related]
9. Ki67 and lymphocytes in the pretherapeutic core biopsy of primary invasive breast cancer: positive markers of therapy response prediction and superior survival.
Schlotter CM; Tietze L; Vogt U; Heinsen CV; Hahn A
Horm Mol Biol Clin Investig; 2017 Sep; 32(2):. PubMed ID: 28937963
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of interferon regulating factor 4 (IRF4) in node-negative breast cancer.
Heimes AS; Madjar K; Edlund K; Battista MJ; Almstedt K; Gebhard S; Foersch S; Rahnenführer J; Brenner W; Hasenburg A; Hengstler JG; Schmidt M
J Cancer Res Clin Oncol; 2017 Jul; 143(7):1123-1131. PubMed ID: 28251349
[TBL] [Abstract][Full Text] [Related]
11. Cytoplasmic FOXP1 expression is correlated with ER and calpain II expression and predicts a poor outcome in breast cancer.
Yu BH; Li BZ; Zhou XY; Shi DR; Yang WT
Diagn Pathol; 2018 May; 13(1):36. PubMed ID: 29848352
[TBL] [Abstract][Full Text] [Related]
12. Strong adverse effect of epidermal growth factor receptor 2 overexpression on prognosis of patients with invasive lobular breast cancer: a comparative study with invasive ductal breast cancer in Chinese population.
Wang T; Ma Y; Wang L; Liu H; Chen M; Niu R
Tumour Biol; 2015 Aug; 36(8):6113-24. PubMed ID: 25804795
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Role of Prolactin-Induced Protein (PIP) in Breast Cancer.
Sauer N; Matkowski I; Bodalska G; Murawski M; Dzięgiel P; Calik J
Cells; 2023 Sep; 12(18):. PubMed ID: 37759471
[TBL] [Abstract][Full Text] [Related]
14. Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.
Skarlos P; Christodoulou C; Kalogeras KT; Eleftheraki AG; Bobos M; Batistatou A; Valavanis C; Tzaida O; Timotheadou E; Kronenwett R; Wirtz RM; Kostopoulos I; Televantou D; Koutselini E; Papaspirou I; Papadimitriou CA; Pectasides D; Gogas H; Aravantinos G; Pavlidis N; Arapantoni P; Skarlos DV; Fountzilas G
Cancer Chemother Pharmacol; 2012 Feb; 69(2):533-46. PubMed ID: 21901395
[TBL] [Abstract][Full Text] [Related]
15. Abundant tumor infiltrating lymphocytes after primary systemic chemotherapy predicts poor prognosis in estrogen receptor-positive/HER2-negative breast cancers.
Watanabe T; Hida AI; Inoue N; Imamura M; Fujimoto Y; Akazawa K; Hirota S; Miyoshi Y
Breast Cancer Res Treat; 2018 Feb; 168(1):135-145. PubMed ID: 29168063
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of autophagy as a new means of improving chemotherapy efficiency in high-LC3B triple-negative breast cancers.
Lefort S; Joffre C; Kieffer Y; Givel AM; Bourachot B; Zago G; Bieche I; Dubois T; Meseure D; Vincent-Salomon A; Camonis J; Mechta-Grigoriou F
Autophagy; 2014; 10(12):2122-42. PubMed ID: 25427136
[TBL] [Abstract][Full Text] [Related]
17. Association of osteopontin with specific prognostic factors and survival in adjuvant breast cancer trials of the Hellenic Cooperative Oncology Group.
Psyrri A; Kalogeras KT; Wirtz RM; Kouvatseas G; Karayannopoulou G; Goussia A; Zagouri F; Veltrup E; Timotheadou E; Gogas H; Koutras A; Lazaridis G; Christodoulou C; Pentheroudakis G; Economopoulou P; Laskarakis A; Arapantoni-Dadioti P; Batistatou A; Sotiropoulou M; Aravantinos G; Papakostas P; Kosmidis P; Pectasides D; Fountzilas G
J Transl Med; 2017 Feb; 15(1):30. PubMed ID: 28193231
[TBL] [Abstract][Full Text] [Related]
18. Molecular biomarkers for prediction of response to treatment and survival in triple negative breast cancer patients from Egypt.
Bahnassy A; Mohanad M; Ismail MF; Shaarawy S; El-Bastawisy A; Zekri AR
Exp Mol Pathol; 2015 Oct; 99(2):303-11. PubMed ID: 26232605
[TBL] [Abstract][Full Text] [Related]
19. Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy.
de Boo L; Cimino-Mathews A; Lubeck Y; Daletzakis A; Opdam M; Sanders J; Hooijberg E; van Rossum A; Loncova Z; Rieder D; Trajanoski Z; Vollebergh M; Sobral-Leite M; van de Vijver K; Broeks A; van der Wiel R; van Tinteren H; Linn S; Horlings HM; Kok M
Eur J Cancer; 2020 Mar; 127():240-250. PubMed ID: 31956037
[TBL] [Abstract][Full Text] [Related]
20. Androgen Receptor Expression in an Indian Breast Cancer Cohort with Relation to Molecular Subtypes and Response to Neoadjuvant Chemotherapy - a Prospective Clinical Study.
Anand A; Singh KR; Kumar S; Husain N; Kushwaha JK; Sonkar AA
Breast Care (Basel); 2017 Jul; 12(3):160-164. PubMed ID: 28785183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
